161 related articles for article (PubMed ID: 36332788)
21. Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy.
Babacan NA; Eroglu Z
Curr Oncol Rep; 2020 Mar; 22(4):38. PubMed ID: 32198651
[TBL] [Abstract][Full Text] [Related]
22. Current status of cancer immunotherapy for gynecologic malignancies.
Nishio H; Iwata T; Aoki D
Jpn J Clin Oncol; 2021 Feb; 51(2):167-172. PubMed ID: 33244581
[TBL] [Abstract][Full Text] [Related]
23. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
[TBL] [Abstract][Full Text] [Related]
24. Immune checkpoint inhibitors in resectable gastroesophageal cancers - a review.
Mukherjee S; Parmar K; Smyth E
Ther Adv Med Oncol; 2022; 14():17588359221139625. PubMed ID: 36479471
[TBL] [Abstract][Full Text] [Related]
25. Ultrasound stiffness and perfusion markers correlate with tumor volume responses to immunotherapy.
Voutouri C; Mpekris F; Panagi M; Krolak C; Michael C; Martin JD; Averkiou MA; Stylianopoulos T
Acta Biomater; 2023 Sep; 167():121-134. PubMed ID: 37321529
[TBL] [Abstract][Full Text] [Related]
26. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy as a partner for HER2-directed therapies.
Clifton GT; Peoples AGE
Expert Rev Anticancer Ther; 2021 Jul; 21(7):739-746. PubMed ID: 33666116
[No Abstract] [Full Text] [Related]
28. The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy.
Ghidini M; Fusco N; Salati M; Khakoo S; Tomasello G; Petrelli F; Trapani D; Petrillo A
Curr Drug Targets; 2021; 22(9):1021-1033. PubMed ID: 33563194
[TBL] [Abstract][Full Text] [Related]
29. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
[TBL] [Abstract][Full Text] [Related]
30. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
31. Harnessing the bioresponsive adhesion of immuno-bioglue for enhanced local immune checkpoint blockade therapy.
Joo KI; Jeong Y; Hwang SM; Shin M; Lee J; Sharma G; Lee H; Im SH; Cha HJ
Biomaterials; 2020 Dec; 263():120380. PubMed ID: 32942128
[TBL] [Abstract][Full Text] [Related]
32. Double Trouble: Immunotherapy Doublets in Melanoma-Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma.
Dimitriou F; Hauschild A; Mehnert JM; Long GV
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-22. PubMed ID: 35658500
[TBL] [Abstract][Full Text] [Related]
33. Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression.
Pu Y; Ji Q
Front Immunol; 2022; 13():874589. PubMed ID: 35592338
[TBL] [Abstract][Full Text] [Related]
34. Revolutionizing the landscape of colorectal cancer treatment: The potential role of immune checkpoint inhibitors.
Tolba MF
Int J Cancer; 2020 Dec; 147(11):2996-3006. PubMed ID: 32415713
[TBL] [Abstract][Full Text] [Related]
35. Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
Levine LS; Mahuron KM; Tsai KK; Wu C; Mattis DM; Pauli ML; Oglesby A; Lee JC; Spitzer MH; Krummel MF; Algazi AP; Rosenblum MD; Alvarado M; Daud AI
Ann Surg Oncol; 2020 Oct; 27(11):4122-4130. PubMed ID: 32488521
[TBL] [Abstract][Full Text] [Related]
36. Immune checkpoint inhibitors for recurrent endometrial cancer.
Mutlu L; Harold J; Tymon-Rosario J; Santin AD
Expert Rev Anticancer Ther; 2022 Mar; 22(3):249-258. PubMed ID: 35176955
[TBL] [Abstract][Full Text] [Related]
37. PD-L1 status in breast cancer: Current view and perspectives.
Vranic S; Cyprian FS; Gatalica Z; Palazzo J
Semin Cancer Biol; 2021 Jul; 72():146-154. PubMed ID: 31883913
[TBL] [Abstract][Full Text] [Related]
38. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
39. Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?
Qian X; Hu W; Yan J
Front Immunol; 2022; 13():963533. PubMed ID: 36016946
[TBL] [Abstract][Full Text] [Related]
40. Gut Microbiota and Therapy in Metastatic Melanoma: Focus on MAPK Pathway Inhibition.
Guardamagna M; Berciano-Guerrero MA; Villaescusa-González B; Perez-Ruiz E; Oliver J; Lavado-Valenzuela R; Rueda-Dominguez A; Barragán I; Queipo-Ortuño MI
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
